FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Uwe Fuhr

Research Profile

Chemicals & Drugs

Physiology

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Khaled Abduljalil; Christoph Gleiter; Job Harenberg; Victoria Kohl; Simone Lazar; Klaus Mörike; Michael Natanzon; Matthias Schwab; Benedict Steffens; Julia Stingl; Dorota Tomalik-Scharte; Weidong Wu; Gregor Zadoyan; Uwe Fuhr
Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.
Oxana Doroshyenko; Angelika Dienel; Thomas Gramatté; Stephan Klement; Hendrik Lück; Dennis Rokitta; Sandra Schläfke; Gregor Vartan Zadoyan; Uwe Fuhr
Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome p450 enzymes in healthy volunteers.
Ahmed Abbas Suleiman; Lucia Nogova; Uwe Fuhr
Modeling NSCLC progression: recent advances and opportunities available.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Uwe Fuhr (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Khaled Abduljalil; Christoph Gleiter; Job Harenberg; Victoria Kohl; Simone Lazar; Klaus Mörike; Michael Natanzon; Matthias Schwab; Benedict Steffens; Julia Stingl; Dorota Tomalik-Scharte; Weidong Wu; Gregor Zadoyan; Uwe Fuhr
Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.
Clinical pharmacokinetics 2013;52(5):359-71.
2013: Oxana Doroshyenko; Angelika Dienel; Thomas Gramatté; Stephan Klement; Hendrik Lück; Dennis Rokitta; Sandra Schläfke; Gregor Vartan Zadoyan; Uwe Fuhr
Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome p450 enzymes in healthy volunteers.
Drug metabolism and disposition: the biological fate of chemicals 2013;41(5):987-93.
2013: Ahmed Abbas Suleiman; Lucia Nogova; Uwe Fuhr
Modeling NSCLC progression: recent advances and opportunities available.
The AAPS journal 2013;15(2):542-50.
2012: Nico Watzek; Denise Scherbl; Dorota Tomalik-Scharte; Matthias Baum; Franz Berger; Oxana Doroshyenko; Gerhard Eisenbrand; Julia Feld; Uwe Fuhr; Elke Richling
Profiling of mercapturic acids of acrolein and acrylamide in human urine after consumption of potato crisps.
Molecular nutrition & food research 2012;56(12):1825-37.
2012: Friederike Kanefendt; Andreas Lindauer; Klaus Mross; Uwe Fuhr; Ulrich Jaehde
Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarker.
Journal of pharmaceutical and biomedical analysis 2012;70():485-91.
2012: Jörg Vehreschild; M J G T Vehreschild; K-A Kreuzer; C Müller; O A Cornely; F Farowski; Uwe Fuhr; M Hallek; V Kohl
Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.
European journal of clinical pharmacology 2012;68(6):987-95.
2012: Gregor Vartan Zadoyan; A Dienel; T Gramatté; R Hoerr; S Klement; D Rokitta; Uwe Fuhr
Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers.
European journal of clinical pharmacology 2012;68(5):553-60.
2012: Natig Gassanov; Amir Nia; Esther Biesenbach; Evren Caglayan; Uwe Fuhr; Fikret Er
Natriuretic peptides in therapy for decompensated heart failure.
European journal of clinical pharmacology 2012;68(3):223-30.
2011: Christian Queckenberg; Mona Tawab; Dorota Tomalik-Scharte; Bertil Wachall; Paola Di Gion; Valerie Erlinghagen; Kathleen Gerbeth; Uwe Fuhr
Pharmacokinetics, pharmacodynamics, and comparative bioavailability of single, oral 2-mg doses of dexamethasone liquid and tablet formulations: a randomized, controlled, crossover study in healthy adult volunteers.
Clinical therapeutics 2011;33(11):1831-41.
2011: Paola Di Gion; Oxana Doroshyenko; Uwe Fuhr; Friederike Kanefendt; Andreas Lindauer; Matthias Scheffler; Jürgen Wolf; Ulrich Jaehde
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
Clinical pharmacokinetics 2011;50(9):551-603.
2011: Matthias Scheffler; Paola Di Gion; Oxana Doroshyenko; Jürgen Wolf; Uwe Fuhr
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
Clinical pharmacokinetics 2011;50(6):371-403.
2011: Dorota Tomalik-Scharte; Uwe Fuhr; Martin Hellmich; Dorothee Frank; Oxana Doroshyenko; Alexander Jetter; Julia C Stingl
Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(5):927-32.
2011: Natig Gassanov; Nasser Semmo; Mariam Semmo; Amir M Nia; Uwe Fuhr; Fikret Er
Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
European journal of clinical pharmacology 2011;67(4):333-46.
2010: Dorota Tomalik-Scharte; Dominique Maiter; Julia Kirchheiner; Hannah E Ivison; Uwe Fuhr; Wiebke Arlt
Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.
European journal of endocrinology / European Federation of Endocrine Societies 2010;163(6):919-24.
2010: Amir M Nia; Uwe Fuhr; Natig Gassanov; Erland Erdmann; Fikret Er
Torsades de pointes tachycardia induced by common cold compound medication containing chlorpheniramine.
European journal of clinical pharmacology 2010;66(11):1173-5.
2010: Uwe Fuhr
Pharmacogenetic-based clinical scores: a useful, simple tool to predict tamoxifen-based CYP2D6 phenotype?
Journal of clinical pharmacology 2010;50(4):370-2.
2010: Alexander Jetter; Gerd Fätkenheuer; Dorothee Frank; Tobias Klaassen; Angela Seeringer; Oxana Doroshyenko; Julia Kirchheiner; Wolfgang Hein; Edgar Schömig; Uwe Fuhr; Christoph Wyen
Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?
Antiviral therapy 2010;15(7):975-83.
2010: V Kohl; Carsten Müller; Oliver A Cornely; K Abduljalil; Uwe Fuhr; Jörg Vehreschild; Christof Scheid; Michael Hallek; M J G T Rüping
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation.
Antimicrobial agents and chemotherapy 2010;54(1):207-12.
2010: Christian Queckenberg; Jürgen Meins; Bertil Wachall; Oxana Doroshyenko; Dorota Tomalik-Scharte; Bärbel Bastian; Mona Abdel-Tawab; Uwe Fuhr
Absorption, pharmacokinetics, and safety of triclosan after dermal administration.
Antimicrobial agents and chemotherapy 2010;54(1):570-2.
2009: Eugen Muschler; Jawahar Lal; Alexander Jetter; Anke Rattay; Ulrich Zanger; Gregor Vartan Zadoyan; Uwe Fuhr; Julia Kirchheiner
The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.
Basic & clinical pharmacology & toxicology 2009;105(6):374-9.
2009: Dorota Tomalik-Scharte; D Lütjohann; Oxana Doroshyenko; D Frank; Alexander Jetter; Uwe Fuhr
Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?
Clinical pharmacology and therapeutics 2009;86(2):147-53.
2009: Khaled Abduljalil; Martina Kinzig; Jürgen Bulitta; Stefan Horkovics-Kovats; Fritz Sörgel; Michael Rodamer; Uwe Fuhr
Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration.
Antimicrobial agents and chemotherapy 2009;53(7):2892-901.
2009: Alexander Jetter; Martina Kinzig; Michael Rodamer; Dorota Tomalik-Scharte; Fritz Sörgel; Uwe Fuhr
Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?
European journal of clinical pharmacology 2009;65(4):411-7.
2009: Oxana Doroshyenko; Uwe Fuhr; Daria Kunz; Dorothee Frank; Martina Kinzig; Alexander Jetter; Yvonne Reith; Andreas Lazar; Dirk Taubert; Julia Kirchheiner; Matthias Baum; Gerhard Eisenbrand; Franz-Ingo Berger; Daniel Bertow; Albrecht Berkessel; Fritz Sörgel; Edgar Schömig; Dorota Tomalik-Scharte
In vivo role of cytochrome P450 2E1 and glutathione-S-transferase activity for acrylamide toxicokinetics in humans.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009;18(2):433-43.
2009: Christian Queckenberg; Uwe Fuhr
Influence of posture on pharmacokinetics.
European journal of clinical pharmacology 2009;65(2):109-19.
2009: Oxana Doroshyenko; Uwe Fuhr
Clinical pharmacokinetics and pharmacodynamics of solifenacin.
Clinical pharmacokinetics 2009;48(5):281-302.
2008: Dorota Tomalik-Scharte; Oxana Doroshyenko; Julia Kirchheiner; Alexander Jetter; Andreas Lazar; Tobias Klaassen; D Frank; Christoph Wyen; Gerd Fätkenheuer; Uwe Fuhr
No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam.
European journal of clinical pharmacology 2008;64(10):1033-5.
2008: Christoph Wyen; Uwe Fuhr; D Frank; R E Aarnoutse; Tobias Klaassen; Andreas Lazar; A Seeringer; Oxana Doroshyenko; J C Kirchheiner; F Abdulrazik; Norbert Schmeisser; Clara Lehmann; W Hein; Edgar Schömig; David Burger; Gerd Fätkenheuer; Alexander Jetter
Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.
Clinical pharmacology and therapeutics 2008;84(1):75-82.
2008: Khaled Abduljalil; Michael Diestelhorst; Oxana Doroshyenko; Anja Lux; Andre Steinfeld; Sven Dinslage; Richard Süverkrüp; Uwe Fuhr
Modelling ocular pharmacokinetics of fluorescein administered as lyophilisate or conventional eye drops.
European journal of clinical pharmacology 2008;64(5):521-9.
2008: Tobias Klaassen; Alexander Jetter; Dorota Tomalik-Scharte; Dirk Kasel; Julia Kirchheiner; Ulrich Jaehde; Uwe Fuhr
Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity.
European journal of clinical pharmacology 2008;64(4):387-98.
2008: Julia Kirchheiner; Ingolf Meineke; Uwe Fuhr; Cristina Rodríguez-Antona; Elena Lebedeva; Jürgen Brockmöller
Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids.
Pharmacogenomics 2008;9(3):277-88.
2008: Uwe Fuhr
Improvement in the handling of drug-drug interactions.
European journal of clinical pharmacology 2008;64(2):167-71.
2008: Dorota Tomalik-Scharte; Andreas Lazar; Uwe Fuhr; Julia Kirchheiner
The clinical role of genetic polymorphisms in drug-metabolizing enzymes.
The pharmacogenomics journal 2008;8(1):4-15.
2008: Simone Stehle; Julia Kirchheiner; Andreas Lazar; Uwe Fuhr
Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
Clinical pharmacokinetics 2008;47(9):565-94.
2007: Uwe Fuhr; Svane Beckmann-Knopp; Alexander Jetter; Hendrik Lück; Ulrich Mengs
The effect of silymarin on oral nifedipine pharmacokinetics.
Planta medica 2007;73(14):1429-35.
2007: M Hunz; Alexander Jetter; Mathias Warm; E Pantke; M Tuscher; Georg Hempel; Ulrich Jaehde; Michael Untch; Christian M Kurbacher; Uwe Fuhr
Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.
Clinical pharmacology and therapeutics 2007;81(5):659-68.
2007: D Frank; Ulrich Jaehde; Uwe Fuhr
Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.
European journal of clinical pharmacology 2007;63(4):321-33.
2007: Uwe Fuhr; Alexander Jetter; Julia Kirchheiner
Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach.
Clinical pharmacology and therapeutics 2007;81(2):270-83.
2007: Stefan Wilde; Alexander Jetter; Stephan Rietbrock; Dirk Kasel; Andreas Engert; Andreas Josting; Beate Klimm; Georg Hempel; Stefanie Reif; Ulrich Jaehde; Ute Merkel; Dagmar Busse; Matthias Schwab; Volker Diehl; Uwe Fuhr
Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.
Clinical pharmacokinetics 2007;46(4):319-33.
2006: Julia Kirchheiner; Soju Thomas; Steffen Bauer; Dorota Tomalik-Scharte; Ursula Hering; Oxana Doroshyenko; Alexander Jetter; Simone Stehle; Martina Tsahuridu; Ingolf Meineke; Jürgen Brockmöller; Uwe Fuhr
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
Clinical pharmacology and therapeutics 2006;80(6):657-67.
2006: Robert Hermann; Jürgen Borlak; U Munzel; Georg Niebch; Uwe Fuhr; Joachim Maus; Katharina Erb
The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine.
The pharmacogenomics journal 2006;6(3):211-9.
2006: Uwe Fuhr; Melanie I Boettcher; Martina Kinzig; Alexandra Weyer; Alexander Jetter; Andreas Lazar; Dirk Taubert; Dorota Tomalik-Scharte; Panagiota Pournara; Verena Jakob; Steffi Harlfinger; Tobias Klaassen; Albrecht Berkessel; Jürgen Angerer; Fritz Sörgel; Edgar Schömig
Toxicokinetics of acrylamide in humans after ingestion of a defined dose in a test meal to improve risk assessment for acrylamide carcinogenicity.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006;15(2):266-71.
2006: Su-arpa Ploylearmsaeng; Uwe Fuhr; Alexander Jetter
How may anticancer chemotherapy with fluorouracil be individualised?
Clinical pharmacokinetics 2006;45(6):567-92.
2005: Uwe Fuhr; J Kirchheiner
Individual variation in factors affecting the steps between dose application and effects of antineoplastic agents.
International journal of clinical pharmacology and therapeutics 2005;43(12):573-4.
2005: Dorota Tomalik-Scharte; Alexander Jetter; Martina Kinzig; Andreas Skott; Fritz Sörgel; Tobias Klaassen; Dirk Kasel; Steffi Harlfinger; Oxana Doroshyenko; D Frank; Julia Kirchheiner; M Bräter; K Richter; T Gramatté; Uwe Fuhr
Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(12):1859-66.
2005: Alexander Jetter; Andreas Lazar; Edgar Schömig; Uwe Fuhr; Martina Kinzig; Fritz Sörgel
The CYP2C9 genotype does not influence sildenafil pharmacokinetics in healthy volunteers.
Clinical pharmacology and therapeutics 2005;78(4):441-3.
2005: Mirko S Faber; Alexander Jetter; Uwe Fuhr
Assessment of CYP1A2 activity in clinical practice: why, how, and when?
Basic & clinical pharmacology & toxicology 2005;97(3):125-34.
2005: Julia Kirchheiner; Uwe Fuhr; Jürgen Brockmöller
Pharmacogenetics-based therapeutic recommendations--ready for clinical practice?
Nature reviews. Drug discovery 2005;4(8):639-47.
2005: Uwe Fuhr; Susan Kober; M Zaigler; Ernst Mutschler; Hilde Spahn-Langguth
Rate-limiting biotransformation of triamterene is mediated by CYP1A2.
International journal of clinical pharmacology and therapeutics 2005;43(7):327-34.
2005: Dorota Tomalik-Scharte; Andreas Lazar; J Meins; B Bastian; M Ihrig; B Wachall; Alexander Jetter; I Tantcheva-Poór; Gustav Mahrle; Uwe Fuhr
Dermal absorption of permethrin following topical administration.
European journal of clinical pharmacology 2005;61(5-6):399-404.
2005: Martina Kinzig; Dorota Tomalik-Scharte; Alexander Jetter; Bernhard Scheidel; Verena Jakob; Michael Rodamer; Ingolf Cascorbi; Oxana Doroshyenko; Fritz Sörgel; Uwe Fuhr
Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?
Antimicrobial agents and chemotherapy 2005;49(5):1733-8.
2005: Fritz Sörgel; Uwe Fuhr; M Minic; M Siegmund; J Maares; Alexander Jetter; Martina Kinzig; Dorota Tomalik-Scharte; J Szymanski; T Goeser; U Toex; B Scheidel; W Lehmacher
Pharmacokinetics of ibuprofen sodium dihydrate and gastrointestinal tolerability of short-term treatment with a novel, rapidly absorbed formulation.
International journal of clinical pharmacology and therapeutics 2005;43(3):140-9.
2005: Oxana Doroshyenko; Alexander Jetter; Karl P Odenthal; Uwe Fuhr
Clinical pharmacokinetics of trospium chloride.
Clinical pharmacokinetics 2005;44(7):701-20.
2004: S Schröder; Alexander Jetter; M Zaigler; R Weyhenmeyer; G Krumbiegel; W Wächter; Uwe Fuhr
Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administration.
International journal of clinical pharmacology and therapeutics 2004;42(10):543-9.
2004: Mirko S Faber; Uwe Fuhr
Time response of cytochrome P450 1A2 activity on cessation of heavy smoking.
Clinical pharmacology and therapeutics 2004;76(2):178-84.
2004: Alexander Jetter; Martina Kinzig; Andreas Skott; Andreas Lazar; Dorota Tomalik-Scharte; Julia Kirchheiner; Monika Walchner-Bonjean; Ursula Hering; Verena Jakob; Michael Rodamer; Wafaâ Jabrane; Dirk Kasel; Jürgen Brockmöller; Uwe Fuhr; Fritz Sörgel
Cytochrome P450 2C9 phenotyping using low-dose tolbutamide.
European journal of clinical pharmacology 2004;60(3):165-71.
2004: Alexander Jetter; Martina Kinzig; Michael Illauer; Robert Hermann; Katharina Erb; Jürgen Borlak; Helga Wolf; Gillian Smith; Ingolf Cascorbi; Fritz Sörgel; Uwe Fuhr
Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure.
European journal of clinical pharmacology 2004;60(1):17-21.
2004: A Lazar; H Menzel; Ingolf Cascorbi; G Kümel; M Sachs; Stephan Rietbrock; Ivar Roots; Uwe Fuhr
CYP1A1 alleles in women with focal nodular hyperplasia of the liver (FNH).
International journal of clinical pharmacology and therapeutics 2004;42(2):78-82.
2004: Tobias Klaassen; Dirk Kasel; Steffi Harlfinger; Uwe Fuhr
Quantification of mephenytoin and its metabolites 4'-hydroxymephenytoin and nirvanol in human urine using a simple sample processing method.
Rapid communications in mass spectrometry : RCM 2004;18(15):1675-80.
2004: Dirk Kasel; Alexander Jetter; Steffi Harlfinger; Wilhelm Gebhardt; Uwe Fuhr
Quantification of cyclophosphamide and its metabolites in urine using liquid chromatography/tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2004;18(13):1472-8.
2004: Markus Riessland; Dorota Tomalik-Scharte; Uwe Fuhr
Do data presented at an American Society for Clinical Pharmacology and Therapeutics meeting make it to full publication?
Clinical pharmacology and therapeutics 2004;75(1):123-4.
2003: Shiba Joseph; James F Rusling; Yuri M Lvov; Thomas Friedberg; Uwe Fuhr
An amperometric biosensor with human CYP3A4 as a novel drug screening tool.
Biochemical pharmacology 2003;65(11):1817-26.
2003: Helmut Schmidt; Stefan Viktor Vormfelde; Monika Walchner-Bonjean; Klaus Klinder; Stefan Freudenthaler; Christoph H Gleiter; Ursula Gundert-Remy; Gisela Skopp; Rolf Aderjan; Uwe Fuhr
The role of active metabolites in dihydrocodeine effects.
International journal of clinical pharmacology and therapeutics 2003;41(3):95-106.
2002: S Wilde; Alexander Jetter; M Zaigier; Stephan Rietbrock; H Menzel; M Sieber; H Tesch; Georg Hempel; Dagmar Busse; Matthias Schwab; Stefanie Reif; Ulrich Jaehde; Volker Diehl; Uwe Fuhr
Population pharmacokinetics of cyclophosphamide, doxorubicin and etoposide in 30 patients with BEACOPP chemotherapy.
International journal of clinical pharmacology and therapeutics 2002;40(12):586-8.
2002: Stefanie Reif; Alexander Jetter; Uwe Fuhr; howard mcleod; Dorothea Kingreen; Wolfgang Siegert; Ulrich Jaehde
Population pharmacokinetics of etoposide.
International journal of clinical pharmacology and therapeutics 2002;40(12):578-9.
2002: Uwe Fuhr; Alexander Jetter
Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions.
Die Pharmazie 2002;57(9):595-601.
2002: Helmut Schmidt; Stefan Viktor Vormfelde; Klaus Klinder; Ursula Gundert-Remy; Christoph H Gleiter; Gisela Skopp; Rolf Aderjan; Uwe Fuhr
Affinities of dihydrocodeine and its metabolites to opioid receptors.
Pharmacology & toxicology 2002;91(2):57-63.
2002: Andreas Labedzki; Jeroen Buters; Wafaâ Jabrane; Uwe Fuhr
Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2.
Biochemical pharmacology 2002;63(12):2159-67.
2002: Uwe Fuhr; Herbert Müller-Peltzer; Rainer Kern; Pablo Lopez-Rojas; Manfred Jünemann; Sebastian Harder; A Horst Staib
Effects of grapefruit juice and smoking on verapamil concentrations in steady state.
European journal of clinical pharmacology 2002;58(1):45-53.
2002: Lars Brachtendorf; Alexander Jetter; K T E Beckurts; Arnulf H Hölscher; Uwe Fuhr
Cytochrome P450 enzymes contributing to demethylation of maprotiline in man.
Pharmacology & toxicology 2002;90(3):144-9.
2002: Alexander Jetter; Martina Kinzig; Monika Walchner-Bonjean; Ursula Hering; Jürgen Bulitta; Philipp Schreiner; Fritz Sörgel; Uwe Fuhr
Effects of grapefruit juice on the pharmacokinetics of sildenafil.
Clinical pharmacology and therapeutics 2002;71(1):21-9.
2001: M Baumhäkel; Dirk Kasel; RA Rao-Schymanski; RH Böcker; K T E Beckurts; M Zaigler; D Barthold; Uwe Fuhr
Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes.
International journal of clinical pharmacology and therapeutics 2001;39(12):517-28.
2001: I Tantcheva-Poór; M Servera-Llaneras; Karin Scharffetter-Kochanek; Uwe Fuhr
Liver cytochrome P450 CYP1A2 is markedly inhibited by systemic but not by bath PUVA in dermatological patients.
The British journal of dermatology 2001;144(6):1127-32.
2001: Alexander Jetter; Uwe Fuhr
[Caution with methylxanthines, antacids or warfarin! Drug interactions with quinolones].
Pharmazie in unserer Zeit 2001;30(5):429-34.
2000: Svane Beckmann-Knopp; Stephan Rietbrock; R Weyhenmeyer; RH Böcker; K T E Beckurts; W Lang; M Hunz; Uwe Fuhr
Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes.
Pharmacology & toxicology 2000;86(6):250-6.
2000: Uwe Fuhr
Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans.
Clinical pharmacokinetics 2000;38(6):493-504.
2000: Uwe Fuhr
[Clinically significant" new drug interactions].
Medizinische Klinik (Munich, Germany : 1983) 2000;95(1 Spec No):18-22.
2000: M Zaigler; Stephan Rietbrock; J Szymanski; J S Dericks-Tan; A Horst Staib; Uwe Fuhr
Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women.
International journal of clinical pharmacology and therapeutics 2000;38(5):235-44.
2000: Heimo Wissing; I Kuhn; Stephan Rietbrock; Uwe Fuhr
Pharmacokinetics of inhaled anaesthetics in a clinical setting: comparison of desflurane, isoflurane and sevoflurane.
British journal of anaesthesia 2000;84(4):443-9.
2000: Stephan Rietbrock; Heimo Wissing; I Kuhn; Uwe Fuhr
Pharmacokinetics of inhaled anaesthetics in a clinical setting: description of a novel method based on routine monitoring data.
British journal of anaesthesia 2000;84(4):437-42.
2000: M Zaigler; I Tantcheva-Poór; Uwe Fuhr
Problems and perspectives of phenotyping for drug-metabolizing enzymes in man.
International journal of clinical pharmacology and therapeutics 2000;38(1):1-9.
1999: Svane Beckmann-Knopp; Stephan Rietbrock; R Weyhenmeyer; RH Böcker; K T E Beckurts; W Lang; Uwe Fuhr
Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes.
Pharmacology & toxicology 1999;85(6):299-304.
1999: K L Rost; Uwe Fuhr; T Thomsen; M Zaigler; J Brockmöller; H Bohnemeier; I Roots
Omeprazole weakly inhibits CYP1A2 activity in man.
International journal of clinical pharmacology and therapeutics 1999;37(11):567-74.
1999: I Tantcheva-Poór; M Zaigler; Stephan Rietbrock; Uwe Fuhr
Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test.
Pharmacogenetics 1999;9(2):131-44.
1999: Martina Kinzig; Uwe Fuhr; M Zaigler; J Dammeyer; G Rüsing; A Labedzki; Jürgen Bulitta; Fritz Sörgel
Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
Clinical pharmacology and therapeutics 1999;65(3):262-74.
1999: Uwe Fuhr
["Clinically significant" new drug interactions].
Medizinische Klinik (Munich, Germany : 1983) 1999;94(2):120-4.
1998: Uwe Fuhr
Tobacco smoking, alcohol, and special diet in drug trials: exclusion criteria or target of specific investigations?
International journal of clinical pharmacology and therapeutics 1998;36(11):604-6.
1998: Martina Kinzig; Uwe Fuhr; M Cesana; C Müller; A Horst Staib; Stephan Rietbrock; Fritz Sörgel
Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state.
Antimicrobial agents and chemotherapy 1998;42(9):2359-64.
1998: Uwe Fuhr
Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance.
Drug safety : an international journal of medical toxicology and drug experience 1998;18(4):251-72.
1998: Uwe Fuhr; A Maier-Brüggemann; H Blume; W Mück; Sigrun Unger; Jochen Kuhlmann; C Huschka; M Zaigler; Stephan Rietbrock; A Horst Staib
Grapefruit juice increases oral nimodipine bioavailability.
International journal of clinical pharmacology and therapeutics 1998;36(3):126-32.
1997: A Horst Staib; Uwe Fuhr
[Theophylline].
Deutsche medizinische Wochenschrift (1946) 1997;122(42):1291-2.
1997: A Horst Staib; R Mäuser; M Zaigler; Uwe Fuhr
[Bioavailability of a new theophylline chewable pill].
Pneumologie (Stuttgart, Germany) 1997;51(6):560-3.
1997: RA Rao-Schymanski; Uwe Fuhr
Pharmacokinetic interactions of antineoplastic agents.
International journal of clinical pharmacology and therapeutics 1997;35(2):84-7.
1996: Uwe Fuhr; K L Rost; R Engelhardt; M Sachs; Dieter Liermann; C Belloc; P Beaune; S Janezic; D Grant; U A Meyer; A Horst Staib
Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.
Pharmacogenetics 1996;6(2):159-76.
1996: Uwe Fuhr; M Weiss; H K Kroemer; G Neugebauer; H Rameis; W Weber; B G Woodcock
Systematic screening for pharmacokinetic interactions during drug development.
International journal of clinical pharmacology and therapeutics 1996;34(4):139-51.
1996: Y Keita; W Wörner; G Veile; B G Woodcock; Uwe Fuhr
Influence of non-steroidal anti-inflammatory drugs on the binding kinetics of dansylsarcosine to human serum albumin. Stereoselectivity, steric and inductive effects.
Arzneimittel-Forschung 1996;46(2):164-8.
1996: H Bode; E Brendel; G Ahr; Uwe Fuhr; S Harder; A Horst Staib
Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine.
European journal of clinical pharmacology 1996;50(3):195-201.
1995: Uwe Fuhr; A L Kummert
The fate of naringin in humans: a key to grapefruit juice-drug interactions?
Clinical pharmacology and therapeutics 1995;58(4):365-73.
1995: Uwe Fuhr; A Maier; A Keller; V W Steinijans; R Sauter; A Horst Staib
Lacking effect of grapefruit juice on theophylline pharmacokinetics.
International journal of clinical pharmacology and therapeutics 1995;33(6):311-4.
1995: Stephan Rietbrock; P G Merz; Uwe Fuhr; Sebastian Harder; J P Marschner; D Loew; J Biehl
Absorption behavior of sulpiride described using Weibull functions.
International journal of clinical pharmacology and therapeutics 1995;33(5):299-303.
1995: A Keller; Uwe Fuhr; R Sauter; V W Steinijans; A Horst Staib
[Pharmacokinetics of a theophylline effervescent tablet].
Die Pharmazie 1995;50(5):356-8.
1994: Uwe Fuhr; A Horst Staib; Sebastian Harder; K Becker; Dieter Liermann; G Schöllnhammer; I S Roed
Absorption of ipsapirone along the human gastrointestinal tract.
British journal of clinical pharmacology 1994;38(1):83-6.
1994: Uwe Fuhr; K L Rost
Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.
Pharmacogenetics 1994;4(3):109-16.
1993: Uwe Fuhr; Johannes Doehmer; N Battula; C Wölfel; I Flick; C Kudla; Y Keita; A Horst Staib
Biotransformation of methylxanthines in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Allocation of metabolic pathways to isoforms and inhibitory effects of quinolones.
Toxicology 1993;82(1-3):169-89.
1993: Uwe Fuhr; K Klittich; A Horst Staib
Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man.
British journal of clinical pharmacology 1993;35(4):431-6.
1993: Uwe Fuhr; G Strobl; F Manaut; E M Anders; Fritz Sörgel; E Lopez-de-Brinas; Daniel T Chu; A G Pernet; Gerhard Mahr; F Sanz
Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2.
Molecular pharmacology 1993;43(2):191-9.
1992: Uwe Fuhr; J Hoyer; W Ritter; A Horst Staib
Differences in absorption of BAY u 3405 along the human gastrointestinal tract.
International journal of clinical pharmacology, therapy, and toxicology 1992;30(11):475-6.
1992: K L Rost; Uwe Fuhr; I Roots; A Horst Staib
Theophylline metabolism affected by mexiletine.
Clinical pharmacology and therapeutics 1992;52(1):107-9.
1992: Uwe Fuhr; E M Anders; Gerhard Mahr; Fritz Sörgel; A Horst Staib
Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro.
Antimicrobial agents and chemotherapy 1992;36(5):942-8.
1992: Uwe Fuhr; Johannes Doehmer; N Battula; C Wölfel; C Kudla; Y Keita; A Horst Staib
Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms.
Biochemical pharmacology 1992;43(2):225-35.
1992: Uwe Fuhr; B G Woodcock; M Siewert
Verapamil and drug metabolism by the cytochrome P450 isoform CYP1A2.
European journal of clinical pharmacology 1992;42(4):463-4.
1992: Gerhard Mahr; Fritz Sörgel; G Richard Granneman; Martina Kinzig; P Muth; K Patterson; Uwe Fuhr; P Nickel; U Stephan
Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine.
Clinical pharmacokinetics 1992;22 Suppl 1():90-7.
1990: Uwe Fuhr; T Wolff; S Harder; P Schymanski; A Horst Staib
Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 1990;18(6):1005-10.
1990: Sebastian Harder; Uwe Fuhr; D Beermann; A Horst Staib
Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule.
British journal of clinical pharmacology 1990;30(1):35-9.
1989: Sebastian Harder; Uwe Fuhr; A Horst Staib; T Wolff
Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations.
The American journal of medicine 1989;87(5A):89S-91S.
1989: A Horst Staib; D Beermann; Sebastian Harder; Uwe Fuhr; Dieter Liermann
Absorption differences of ciprofloxacin along the human gastrointestinal tract determined using a remote-control drug delivery device (HF-capsule).
The American journal of medicine 1989;87(5A):66S-69S.
1989: A M Wittenbrink-Dix; G Neugebauer; Uwe Fuhr; P Neubert; E Besenfelder; E Woelke-Seidl; S Harder; A Horst Staib
Study of potential kinetic interactions of picumast dihydrochloride and theophylline in vitro and after oral administration in man.
Arzneimittel-Forschung 1989;39(10A):1339-43.
1989: A Horst Staib; Sebastian Harder; Uwe Fuhr; C Wack
Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid.
International journal of clinical pharmacology, therapy, and toxicology 1989;27(6):289-3.
1989: Uwe Fuhr; S Harder; S Häfner; D Rosenthal; R Lorenz; A Horst Staib
CSF pharmacokinetics of ceftazidime in neurosurgical patients with an external ventriculostomy.
Infection 1989;17(1):15-6.